4-Pyrazoleboronic acid pinacol ester

• Catalog No.: 525057
• CAS Number: 269410-08-4
• M. F.: C9H15BN2O2
• M. W.: 194.0386
• Purity: 97%

SYNONYMS

• Title: 4-吡唑硼酸频哪醇酯
• IUPAC name: 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• IUPAC Traditional name: 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 4,4,5,5-Tetramethyl-2-(pyrazol-4-yl)-1,3,2-dioxaborolane; 4,4,5,5-Tetramethyl-2-(1H-pyrazol-4-yl)-1,3,2-dioxaborolane; 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole; Pyrazol-4-ylboronic acid pinacol ester; 4,4,5,5-Tetramethyl-2-(1H-pyrazol-2-yl)-1,3,2-dioxaborolane; 4,4,5,5-四甲基-2-(1H-吡唑-4-基)-1,3,2-二氧杂戊硼烷

DATABASE IDS

• MDL Number: MFCD03453063
• CAS Number: 269410-08-4
• PubChem SID: 24874465

PROPERTIES

• Linear Formula: (CH3)4C2O2BC3N2H3
• Purity: 97%
• Melting Point: 142-146 °C(lit.)
• GHS Signal Word: Warning
• GHS Hazard statements: H315-H319-H335
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P261-P305 + P351 + P338
• Risk Statements: 36/37/38
• Safety Statements: 26-36
• German water hazard class: 3

DETAILS

Description (English)

Packaging
1, 5, 25 g in glass bottle
Legal Information
Product of Boron Molecular
Application
Reagent used for
• Suzuki-Miyaura cross-couplings1
• Ruthenium-catalyzed asymmetric hydrogenation2 Reagent used in preparation of inhibitors of many highly significant therapeutic enzymes and kinases containing the privileged scaffold pyrazole, including
• VEGF3
• Aurora3,4
• Rho (ROCK)2
• Janus Kinase 2 (JAK)5
• c-MET6
• ALK6
• S-nitrosoglutathione reductase7
• CDC78
• Acetyl-CoA carboxylase9
• Prosurvival Bcl-2 protein10
• Viral RNA-Dependent RNA polymerase11
• Long Chain Fatty Acid Elongase 612
• PI313
• AKT14
• Chk115
• Protein Kinase B16

Description (简体中文)

包装
1, 5, 25 g in glass bottle
Legal Information
Boron Molecular 制造
Application
Reagent used for
• Suzuki-Miyaura cross-couplings1
• Ruthenium-catalyzed asymmetric hydrogenation2 Reagent used in preparation of inhibitors of many highly significant therapeutic enzymes and kinases containing the privileged scaffold pyrazole, including
• VEGF3
• Aurora3,4
• Rho (ROCK)2
• Janus Kinase 2 (JAK)5
• c-MET6
• ALK6
• S-nitrosoglutathione reductase7
• CDC78
• Acetyl-CoA carboxylase9
• Prosurvival Bcl-2 protein10
• Viral RNA-Dependent RNA polymerase11
• Long Chain Fatty Acid Elongase 612
• PI313
• AKT14
• Chk115
• Protein Kinase B16